Disease · MONDO_0100192
Targets38
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 38
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Unknown | https://conductscience.org/library/genes/1441 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Early phase 1 | https://conductscience.org/library/genes/727 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Unknown | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Unknown | https://conductscience.org/library/genes/942 | Drugs and targets |
| COMT | Catechol O-methyltransferase | 1 | Catechol O-methyltransferase inhibitor | Approval | https://conductscience.org/library/genes/1312 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Early phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 1 | Interferon alpha/beta receptor agonist | Unknown | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 1 | Interferon alpha/beta receptor agonist | Unknown | https://conductscience.org/library/genes/3455 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Early phase 1 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Early phase 1 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Early phase 1 | https://conductscience.org/library/genes/931 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE10A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/10846 | Drugs and targets |
| PDE1A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5136 | Drugs and targets |
| PDE1B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5153 | Drugs and targets |
| PDE1C | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5137 | Drugs and targets |
| PDE2A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5138 | Drugs and targets |
| PDE3A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5139 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100192/targets